A rapid antimicrobial susceptibility test based on chemiluminescence assay and its application to screening of genotypes in vancomycin-resistant enterococci

Nagasawa, Zenzo; Manome, Isao; Nagayama, Ariaki

doi:10.1007/s10156-004-0329-z

Cited by 8 publications

(2 citation statements)

References 24 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an initial study, the rapid chemiluminescence assay (developed by Eiken Chemicals, Tokyo, Japan) showed 100% sensitivity in determining vanA, vanB, vanC-1, and vanC2/3 genotypes in a small number of isolates [46]. Similar results, using isolates, were reported using two recently developed detection kits for VRE which use DNA probe hybridization: the EVIGENE assay (Statens Serum Institute, Denmark) and the Velogene Genomic Assay (ID Biomed, Bothell, Washington, USA) [47,48].…”

Section: Detection Of Vancomycin Resistant Enterococci Detectionmentioning

confidence: 99%

Epidemiology and mechanisms of glycopeptide resistance in enterococci

Zirakzadeh

Patel

2005

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

show abstract

Section: Detection Of Vancomycin Resistant Enterococci Detectionmentioning

confidence: 99%

Epidemiology and mechanisms of glycopeptide resistance in enterococci

Zirakzadeh

Patel

2005

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Assays for rapid identification of VRE are also under development. A novel susceptibility test based on a chemiluminescence assay found that PCR is reliable and rapid for detection of VRE strains in clinical laboratories, and is associated with a very short incubation time (2-4 h) [10]. These new assays will require further clinical validation.…”

Section: Napolitanomentioning

confidence: 99%

Emerging Issues in the Diagnosis and Management of Infections Caused by Multi-Drug-Resistant, Gram-Positive Cocci

Napolitano

2005

Surgical Infections

View full text Add to dashboard Cite

Background: Rising rates of multi-drug-resistant, gram-positive cocci (e.g., methicillin-resistant Staphylococcus aureus [MRSA], vancomycin-resistant Enterococcus spp. [VRE]) have created treatment challenges for clinicians in both the hospital and community settings. These organisms have become especially problematic for hospitalized patients with pneumonia, complicated intra-abdominal infections, and skin and skin-structure infections (SSSIs). Methods: A review of the recent literature (1990 onwards) was undertaken in order to review the epidemiology, diagnostic issues, and clinical trial data of available and forthcoming therapies for the treatment of multi-drug resistant, gram-positive isolates, with an emphasis on selected MRSA infections (i.e., pneumonia, SSSI, diabetic foot infections, blood stream) and infections caused by VRE. Results: The rate of healthcare-associated MRSA in 2004 rose to an incidence of 59.5% in the United States compared with data from 1998-2002, making MRSA the predominant grampositive etiology of S. aureus infections in hospitalized patients. Methicillin-resistant S. aureus has also emerged as an important pathogen in both the non-ICU and community settings. Similarly, 28.5% of all enterococcal isolates were identified as vancomycin-resistant in 2003 (a 12% increase). However, these rates may be underestimated, as detection methods for determining susceptibility have proved to be inadequate. Recognition that prior inadequate antibiotic therapy is common in patients with antibiotic-resistant bacteria, and is associated with higher mortality rates, emphasizes the importance of selecting appropriate empiric therapy. Currently available therapies for resistant gram-positive infections include quinupristindalfopristin, linezolid, and daptomycin, although each of these agents has limitations (e.g., daptomycin is not indicated for MRSA pneumonia due to inadequate lung tissue penetration and inactivation by surfactant). Three agents with broad-spectrum activity against gram-positive organisms that are at an advanced stage of testing include two new glycopeptides (oritavancin and dalbavancin), and a first-in-class glycylcycline (tigecycline). These agents have demonstrated efficacy in the treatment of SSSIs, including those caused by MRSA. Conclusions: New antimicrobial agents are needed to combat the increasing prevalence of multi-drug-resistant, gram-positive pathogens such as MRSA. The emergence of resistance to available therapies such as vancomycin underscores this urgency.

show abstract

Characterization of Clinical Isolates of Gordonia Species in Japanese Clinical Samples During 1998–2008

et al. 2009

View full text Add to dashboard Cite

During 1998-2008, there were 31 strains of Gordonia species isolated from clinical specimens in our laboratory. Our identification of the 31 strains of Gordonia species showed that major pathogenic Gordonia species in Japan were classifiable, respectively into 14 and 13 strains of Gordonia sputi and Gordonia bronchialis. The four remaining strains were identified as three Gordonia species: G. aichiensis (2 strains), and G. terrae (1 strain), and G. otitidis (1 strain). Results of drug susceptibility tests for these 31 strains of Gordonia isolates are reported herein.

show abstract

A rapid antimicrobial susceptibility test based on chemiluminescence assay and its application to screening of genotypes in vancomycin-resistant enterococci

Cited by 8 publications

References 24 publications

Epidemiology and mechanisms of glycopeptide resistance in enterococci

Epidemiology and mechanisms of glycopeptide resistance in enterococci

Emerging Issues in the Diagnosis and Management of Infections Caused by Multi-Drug-Resistant, Gram-Positive Cocci

Characterization of Clinical Isolates of Gordonia Species in Japanese Clinical Samples During 1998–2008

Contact Info

Product

Resources

About